* patient is moribund or has an estimated life expectancy \<1 month (e.g., terminal cancer, etc.) * patient is anticipated to be discharged from hospital within 48 hours * patient requires anti-inflammatory medicines beyond soc (soc are drugs that are approved for treatment of covid-19 as well as medicines that have been recommended in treatment guidelines of national health authorities and/or professional organization) * patient requires invasive mechanical ventilation * patient is known to have active tuberculosis * patient is known to have hereditary fructose intolerance. * patient is known to have co-infection with influenza viruses or other viral respiratory infections (respiratory syncytial virus \[rsv\], parainfluenza viruses, respiratory adenoviruses).

* patient is moribund or has an estimated life expectancy \<1 month (e.g., terminal cancer, etc.) * patient is anticipated to be discharged from hospital within 48 hours * patient requires anti-inflammatory medicines beyond soc (soc are drugs that are approved for treatment of covid-19 as well as medicines that have been recommended in treatment guidelines of national health authorities and/or professional organization) * patient requires invasive mechanical ventilation * patient is known to have active tuberculosis * patient is known to have hereditary fructose intolerance. * patient is known to have co-infection with influenza viruses or other viral respiratory infections (respiratory syncytial virus \[rsv\], parainfluenza viruses, respiratory adenoviruses).

patient is moribund or has an estimated life expectancy <1 month (e.g., terminal cancer, etc.) patient is anticipated to be discharged from hospital within 48 hours patient requires anti-inflammatory medicines beyond soc (soc are drugs that are approved for treatment of covid-19 as well as medicines that have been recommended in treatment guidelines of national health authorities and/or professional organization) patient requires invasive mechanical ventilation patient is known to have active tuberculosis patient is known to have hereditary fructose intolerance. patient is known to have co-infection with influenza viruses or other viral respiratory infections (respiratory syncytial virus [rsv], parainfluenza viruses, respiratory adenoviruses).

patient is moribund or has an estimated life expectancy <1 month (e.g., terminal cancer, etc.) patient is anticipated to be discharged from hospital within 48 hours patient requires anti-inflammatory medicines beyond soc (soc are drugs that are approved for treatment of covid-19 as well as medicines that have been recommended in treatment guidelines of national health authorities and/or professional organization) patient requires invasive mechanical ventilation patient is known to have active tuberculosis patient is known to have hereditary fructose intolerance. patient is known to have co-infection with influenza viruses or other viral respiratory infections (respiratory syncytial virus [rsv], parainfluenza viruses, respiratory adenoviruses).